Tanshinone IIA CAS 568-72-9: A Potent Pharmaceutical Intermediate for Cancer Research

Discover the extensive research on Tanshinone IIA, a key pharmaceutical intermediate with significant anticancer properties. Learn about its mechanisms of action and its potential in drug discovery and development from a trusted supplier.

Get a Quote & Sample

Key Advantages of Sourcing Tanshinone IIA

Extensive Anticancer Mechanisms

Tanshinone IIA exhibits broad-spectrum anticancer activity by inducing apoptosis, regulating cell cycle progression, and inhibiting critical signaling pathways such as PI3K/Akt/mTOR and Ras/MAPK, making it a valuable intermediate for cancer drug discovery.

Natural Origin and High Purity

Sourced from Salvia miltiorrhiza, Tanshinone IIA offers a natural alternative with a well-defined mechanism of action. We ensure high purity and quality, critical for reliable research and pharmaceutical applications.

Synergistic Therapeutic Potential

Research indicates Tanshinone IIA can act synergistically with conventional treatments like Hsp90 inhibitors, enhancing their antitumor efficacy. This positions it as a promising agent for combination therapies, offering enhanced treatment outcomes.

Applications in Pharmaceutical Research

Cancer Drug Discovery

As a potent intermediate, Tanshinone IIA is instrumental in the discovery and development of novel anticancer drugs, offering a natural compound with a complex biological activity profile for pharmaceutical manufacturers.

Mechanism of Action Studies

Its well-documented interactions with various signaling pathways make Tanshinone IIA an excellent subject for understanding cancer biology and developing targeted therapies. Buy Tanshinone IIA for advanced research.

Preclinical Research

Reliable supply of Tanshinone IIA from our China-based facilities supports preclinical studies aimed at evaluating its efficacy and safety in various cancer models.

Pharmaceutical Intermediate Sourcing

We are a trusted supplier providing high-quality Tanshinone IIA, essential for pharmaceutical companies seeking to synthesize new therapeutic agents.